JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

TikToker Insightful Lucy has revealed the four things she wished she had known before starting Mounjaro, after losing six stone on the medication.

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three ...

Once users stop taking Mounjaro, their appetite is no longer suppressed, and there's a decent chance that they will revert ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

A high-level overview of Eli Lilly and Company (LLY) stock. View (LLY) real-time stock price, chart, news, analysis, analyst reviews and more.

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...